These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

4782 related items for PubMed ID: 9021355

  • 1. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R, Messinis LE, Fowler P, Groome NP, Knight PG, Templeton AA.
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
    Heikinheimo O, Gordon K, Williams RF, Hodgen GD.
    Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
    [Abstract] [Full Text] [Related]

  • 3. Changes in gonadotrophin response to gonadotrophin releasing hormone in normal women following bilateral ovariectomy.
    Alexandris E, Milingos S, Kollios G, Seferiadis K, Lolis D, Messinis IE.
    Clin Endocrinol (Oxf); 1997 Dec; 47(6):721-6. PubMed ID: 9497880
    [Abstract] [Full Text] [Related]

  • 4. Failure of oestrogen induced luteinizing hormone surge in women treated with mifepristone (RU 486) every day for 30 days.
    Baird DT, Thong KJ, Hall C, Cameron ST.
    Hum Reprod; 1995 Sep; 10(9):2270-6. PubMed ID: 8530650
    [Abstract] [Full Text] [Related]

  • 5. Effects of an antiprogesterone (RU486) on the hypothalamic-hypophyseal-ovarian-endometrial axis during the luteal phase of the menstrual cycle.
    Garzo VG, Liu J, Ulmann A, Baulieu E, Yen SS.
    J Clin Endocrinol Metab; 1988 Mar; 66(3):508-17. PubMed ID: 2832438
    [Abstract] [Full Text] [Related]

  • 6. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth.
    Cameron ST, Thong KJ, Baird DT.
    Clin Endocrinol (Oxf); 1995 Oct; 43(4):407-14. PubMed ID: 7586613
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The effects of estrogen and progesterone on the functional capacity of the gonadotrophs.
    Lasley BL, Wang CF, Yen SS.
    J Clin Endocrinol Metab; 1975 Nov; 41(5):820-6. PubMed ID: 1102551
    [Abstract] [Full Text] [Related]

  • 12. Accelerated dissolution of luteal-endometrial integrity by the administration of antagonists of gonadotropin-releasing hormone and progesterone to late-luteal phase women.
    Roseff SJ, Kettel LM, Rivier J, Burger HG, Baulieu E, Yen SS.
    Fertil Steril; 1990 Nov; 54(5):805-10. PubMed ID: 2226914
    [Abstract] [Full Text] [Related]

  • 13. Role of gonadotrophin releasing hormone baseline concentrations in the control of pituitary gonadotrophin and ovarian steroid secretion in the pseudopregnant rat.
    Schuiling GA, Valkhof N, Koiter TR.
    Hum Reprod; 1996 Jan; 11(1):13-8. PubMed ID: 8671150
    [Abstract] [Full Text] [Related]

  • 14. The sequence of pituitary responses to synthetic luteinizing hormone releasing hormone (LH-RH) throughout the normal menstrual cycle.
    Grimes EM, Thompson IE, Taymor ML.
    Acta Endocrinol (Copenh); 1975 Aug; 79(4):625-34. PubMed ID: 1098349
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Interference with ovulation by sequential treatment with the antiprogesterone RU486 and synthetic progestin.
    Kekkonen R, Alfthan H, Haukkamaa M, Heikinheimo O, Luukkainen T, Lähteenmäki P.
    Fertil Steril; 1990 Apr; 53(4):747-50. PubMed ID: 2108063
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of follicle stimulating hormone or human chorionic gonadotrophin treatment on the production of gonadotrophin surge attenuating factor (GnSAF) during the luteal phase of the human menstrual cycle.
    Messinis IE, Lolis D, Zikopoulos K, Milingos S, Kollios G, Seferiadis K, Templeton AA.
    Clin Endocrinol (Oxf); 1996 Feb; 44(2):169-75. PubMed ID: 8849571
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 240.